The results of the present study indicate that SYF regulates the expression of genes involved in cell proliferation, migration, and invasion by regulating the JAK/STAT3 signalling pathway and finally enhances the therapeutic efficacy of paclitaxel in triple-negative breast cancer (Figure 9C). The gene discussed is STAT3; the disease is triple-negative breast carcinoma.